Not Signed In -
Amlodipine and Benazepril |
Lotrel |
Clinical Trial: Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients with Type 2 Diabetes Mellitus
This study is no longer recruiting patients.
|
Purpose
Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein which develops with kidney disease. This study will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary protein in hypertensive subjects with type 2 diabetes mellitus.
| Condition | Intervention | Phase |
|---|---|---|
| Albuminuria | Drug: amlodipine/benazepril | Phase IV |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Further Study Details:
Study start: April 2003
Eligibility
Ages Eligible for Study: 21 Years - 85 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Mild to moderate hypertension
- Type 2 diabetes mellitus
- Presence of protein in the urine (albuminuria)
Exclusion Criteria:
More Information
Study ID Numbers: CCIB002FUS12
Last Updated: August 26, 2005
Record first received: August 25, 2005
ClinicalTrials.gov Identifier: NCT00136773
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: August 26, 2005
Record first received: August 25, 2005
ClinicalTrials.gov Identifier: NCT00136773
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Amlodipine and Benazepril (Drug Digest)
- Lotrel (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
